Technology Appraisal Committee Meeting (Committee C)

Minutes: Confirmed

Date and Time: Wednesday 30 May 2018, 10:00 – 15:00

Venue: National Institute for Health and Care Excellence
Level 1A, City Tower
Piccadilly Plaza
Manchester
M1 4BT

Present: 1. Chair Professor Stephen O’Brien Present for all notes
2. Dr Alex Cale Present for all notes
3. Mr Michael Chambers Present for all notes
4. Dr David Chandler Present for all notes
5. Ms Gail Coster Present for all notes
6. Dr Prithviraj Das Present for all notes
7. Dr Natalie Hallas Present for all notes
8. Mr John Hampson Present for all notes
9. Dr Nigel Langford Present for all notes
10. Dr Rubin Minhas Present for all notes
11. Dr Richard Nicholas Present for all notes
12. Prof Andrew Renehan Present for all notes
13. Dr Peter Selby Present for all notes
14. Dr Paul Tappenden Present for all notes
15. Dr Derek Ward Present for all notes
16. Dr Judith Wardle Present for all notes

In attendance:

Helen Knight Acting Programme Director, National Institute for Health and Care Excellence Present for all notes

Frances Sutcliffe Associate Director, National Institute for Health and Care Excellence Present for all notes

Stephanie Callaghan Project Manager, National Institute for Health and Care Excellence Present for all notes

Gemma Barnacle Project Manager, National Institute for Health and Care Excellence Present for all notes
Welcome

1. The Chair welcomed all members of the Committee and other attendees present to the meeting. The Chair reviewed the agenda and timescales for the meeting, which included the appraisals of lenvatinib for advanced, unresectable, untreated hepatocellular carcinoma [ID1089]

2. The Chair informed the Committee of the non-public observers at this meeting: Lesley Hayes

3. Apologies were received from Mr Kamal Balakrishnan, Prof Andrew Manca, Prof Matt Stevenson and Prof Robert Walton.

Any other Business

4. Ross Dent answered questions from the committee about the technical report stage and gathered feedback
Appraisal of lenvatinib for advanced, unresectable, untreated hepatocellular carcinoma [ID1089]

Part 1 – Open session

5. The Chair welcomed the invited experts: Charles Gore, Syed Hyder Hussaini, Tim Meyer, Peter Cain, Steve Edwards and Kayleigh Kew to the meeting and they introduced themselves to the Committee.

6. The Chair welcomed company representatives from Eisai to the meeting.

7. The Chair asked all Committee members to declare any relevant interests

7.1. Dr Alex Cale, Mr Michael Chambers, Mr David Chandler, Ms Gail Coster, Dr Prithviraj Das, Dr Natalie Hallas, Mr John Hampson, Dr Nigel Langford, Dr Rubin Minhas, Dr Richard Nicholas, Prof Andrew Renehan, Dr Peter Selby, Dr Paul Tappenden, Dr Derek Ward and Dr Judith Wardle all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of lenvatinib for advanced, unresectable, untreated hepatocellular carcinoma.

8. The Chair asked all NICE Staff to declare any relevant interests.

8.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of lenvatinib for advanced, unresectable, untreated hepatocellular carcinoma.

9. The Chair asked all other invited guests (assessment group/ERG and invited experts, not including observers) to declare their relevant interests.

9.1. Peter Cain, Steve Edwards, Kayleigh Kew, Charles Gore and Syed Hyder Hussaini declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of lenvatinib for advanced, unresectable, untreated hepatocellular carcinoma.

9.2. Tim Meyer declared a personal non-specific financial interest as he has participated in an advisory board for the company who market this technology.

9.2.1. It was agreed that this declaration would not prevent Tim Meyer from participating in this section of the meeting.

10. The Chair introduced the lead team, Mr David Chandler, Ms Gail Coster and Dr Natalie Hallas who gave presentations on the clinical effectiveness and cost
effectiveness of lenvatinib for advanced, unresectable, untreated hepatocellular carcinoma.

11. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.

12. The Chair then thanked the experts and company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

Part 2 – Closed session

13. Discussion on confidential information continued. This information was supplied by the company.

14. The Committee continued to discuss the clinical and cost effectiveness of lenvatinib for advanced, unresectable, untreated hepatocellular carcinoma.

14.1. The committee decision was based on consensus.

15. The Committee instructed the technical team to prepare the Appraisal Consultation Document (ACD)

Date, time and venue of the next meeting

16. Wednesday 27 June 2018, 10:00 – 17:00 at National Institute for Health and Care Excellence, Level 1A, City Tower, Piccadilly Plaza, Manchester M1 4BT.